869663-58-1

Upstream product

• 59997-51-2 trimethylacetylacetonitrile 
• 54049-23-9 4-hydroxyphenylhydrazine hydrochloride 
• 3471-32-7 4-Methoxyphenylhydrazine 
• 227623-26-9 3-tert-butyl-1-(4-methoxyphenyl)-1H-pyrazol-5-amine 

Downstream Products

• 1443248-12-1 5-tert-butyl-2-{4-[2-(4-methyl-piperazin-1-yl)-ethoxy]-phenyl}-2H-pyrazol-3-ylamine 
• 876301-36-9 3-tert-butyl-1-(4-(tert-butyldimethyl-silyloxy)phenyl)-1H-pyrazol-5-amine 
• 1443248-15-4 (5-tert-butyl-2-{4-[2-(4-methyl-piperazin-1-yl)-ethoxy]-phenyl}-2H-pyrazol-3-yl)-N,N-bis-carbamic acid 2,2,2-trichloro-ethyl ester 
• 1241507-55-0 3-tert-butyl-1-(4-(2-morpholinoethoxy) phenyl)-1H-pyrazol-5-amine 

Relevant academic research and scientific papers

POLYAROMATIC UREA DERIVATIVES AND THEIR USE IN THE TREATMENT OF MUSCLE DISEASES

The current invention provides urea derivatives, in particular compounds having the core structure heteroaryl-NH-CO-NH-aryl-O- heteroaryl, for use in treating, ameliorating, delaying, curing and/ or preventing a disease or condition associated with muscle cells and/or satellite cells, such as Duchenne muscular dystrophy, Becker muscular dystrophy, cachexia or sarcopenia.

ANTI-MUCUS DRUGS AND USES THEREFOR

Disclosed are methods of identifying, generating and synthesizing compounds that inhibit MAPK13 activity. In various embodiments, compounds, salts thereof and prodrugs thereof of the present teachings can be useful for the treatment of diseases and disord

KINASE INHIBITORS

Compounds of formula (I) or a pharmaceutically acceptable salt thereof: wherein R2, W, A, Y and R1 are as defined in the specification, are p38 MAPK inhibitors, useful as anti-inflammatory agents in the treatment of, inter alia, diseases of the respiratory tract.

KINASE INHIBITORS

Compounds of formula (I): wherein R2, W, A, Y, and R1 are as defined in the specification, and pharmaceutically acceptable salts thereof, are p38 MAPK inhibitors, and are useful as anti-inflammatory agents in the treatment of, inter alia, diseases of the respiratory tract.

PYRAZOLE P38 MAP KINASE INHIBITORS

There are provided inter alia compounds of formula (I): wherein R1, R2a, R2b, R3, R4, L, X, R5 and R6 are as defined in the description for use in the treatment of inflammatory diseases.

PYRAZOLE P38 MAP KINASE INHIBITORS

There are provided inter alia compounds of formula (I): wherein R1, R2a, R2b, R3, R4, L, X, R5 and R6 are as defined in the description for use in the treatment of inflammatory diseases.

UREA COMPOUNDS USEFUL IN THE TREATMENT OF CANCER

Pyrazole urea compounds, pharmaceutical compositions which contain them and methods for treating cancer using them.

Triazolopyridinylsulfanyl derivatives as p38 MAP kinase inhibitors

A compound of formula (I), or a pharmaceutically acceptable salt and/or solvate (including hydrate) thereof; and the use of a compound of formula (I) in the treatment of a TNF-mediated disease, disorder, or condition, or a p38-mediated disease, disorder, or condition, in particular the allergic and non-allergic airways diseases, more particularly obstructive or inflammatory airways diseases, preferably chronic obstructive pulmonary disease.